Trial reportThe pharmacogenomics journal2026
Risk of drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele.
Trial report in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KM-819, a first-in-class inhibitor of Fas-associated factor 1 (FAF1), was investigated in a Phase 2 clinical trial in Korean patients with multiple system atrophy (MSA). Among 34 KM-819-treated patients, 11 met the case definition for suspected DILI, and 9 of these (26%) were adjudicated by an independent hepatic adjudication committee (HAC) as KM-819-related DILI; no cases occurred among the 34 patients receiving placebo. Blood samples for genetic analysis were available from only 6 of the 9 adjudicated DILI cases; therefore, an exploratory comparative genetic analysis was performed using DNA samples from a total of 16 patients treated with KM-819, including the 6 available DILI cases and 10 patients without DILI. Whole-genome sequencing (WGS) identified the HLA-DPB1*05:01:01:01 allele in all 6 patients with DILI, compared to only 1 of the 10 patients without DILI (p = 0.0009), suggesting a potential association between HLA-DPB1*05:01:01:01 and DILI due to KM-819. In this discovery cohort, HLA-DPB1*05:01:01:01 showed 100% sensitivity, 90.0% specificity, a positive predictive value (PPV) of 85.7%, and a negative predictive value (NPV) of 100% for DILI due to KM-819, albeit with wide confidence intervals reflecting the small sample size. Given the small sample size, exploratory nature of the analysis, and use of the same cohort for both discovery and performance estimation, these findings should be considered hypothesis-generating. Therefore, HLA-DPB1*05:01:01:01 should be regarded as a candidate risk marker specific to this Korean cohort, requiring validation in larger, independent, and ethnically diverse cohorts before its application in clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.